



Medtronic Initiates Pivotal Trial for Next-Generation Guardian(TM) Continuous Glucose Monitoring Sensor

June 8, 2019



DUBLIN - June 8, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has initiated the company's pivotal trial for its next-generation Guardian(TM) continuous glucose monitoring (CGM) sensor designed to improve accuracy and overall system performance, reduce sensor calibrations and enhance overall user experience. The multi-center, prospective trial will study the next-generation CGM sensor in up to 460 participants with type 1 or type 2 diabetes aged two to 80 years old over the course of seven days. Study participants will be randomly assigned to sensor wear location and testing days and times.

"We are very excited about this next-generation CGM sensor as it is designed to require calibrations only on the first day of wear, reducing fingersticks by 95% over our current CGM," said Ali Dianaty, vice president of research & development for the Diabetes Group at Medtronic. "We strongly believe calibration on the first day of wear is necessary to improve day one performance, which we know from physician and patient feedback is a challenge for all sensors. Our research shows this day one performance is critical for keeping patients safe in hybrid closed loop, or Auto Mode, which we know from real-world experience delivers the optimal Time in Range for patients on insulin therapy."

"This is a very positive next step to enhancing the overall experience with Medtronic hybrid closed loop systems with enhanced sensors that really focus on the patient experience. It's great to see that these advancements are being informed by robust real-world use of Medtronic therapies with an emphasis on ensuring that these important technologies are not only delivering best-in-class outcomes but also prioritizing ease of use," said Dr. Bruce Bode, clinical associate professor at Emory University in the Department of Medicine and co-principal investigator of the study.

For more details, including enrollment information for the trial, please visit <https://clinicaltrials.gov/ct2/show/NCT03966911>.

About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)

Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Contacts:

Kendra Cassillo
Public Relations
+1-818-576-5611

Ryan Weispfenning
Investor Relations
+1-763-505-4626